Scientific Sessions 2025  /  Innovations and Challenges in Preclinical Studies of Group 2 and Group 3 PH  /  Heterogeneity Among Preclinical Models of Group 2 or Group 3 PH: Myth or Reality?
Logo

American Heart Association

  43
  0

Final ID:

Heterogeneity Among Preclinical Models of Group 2 or Group 3 PH: Myth or Reality?

  • Lai, Yen Chun  ( Indiana University , Indianapolis , Indiana , United States )
  • Shimoda, Larissa  ( JOHNS HOPKINS SCHOOL OF MEDICINE , Baltimore , Maryland , United States )
  • Goncharova, Elena  ( University of California, Davis , Davis , California , United States )
    • Author Disclosures:
    Yen Chun Lai: DO NOT have relevant financial relationships | Larissa Shimoda: No Answer | Elena Goncharova: DO NOT have relevant financial relationships
Meeting Info:

Scientific Sessions 2025

2025

New Orleans, Louisiana

Session Info:

Innovations and Challenges in Preclinical Studies of Group 2 and Group 3 PH

Monday, 11/10/2025 , 08:00AM - 09:15AM

Cardiovascular Seminar

More abstracts on this topic:
Finding Drugs to Repurpose for Groups 2 and 3 PH: Is There Hope?

Spiekerkoetter Edda, Toshner Mark, Prins Kurt

Combined Pre- and Post-Capillary PH: What Models Do We Use to Study the Disease?

Agrawal Vineet, Brittain Evan, Maron Brad

More abstracts from these authors:
Epigenetic Mechanisms of Pulmonary Vascular Remodeling in Pulmonary Hypertension

Hadri Lahouaria, Stenmark Kurt, Goncharova Elena, Bonnet Sebastien

NHE1 Regulates Apoptosis Susceptibility in Sugen-Hypoxia Pulmonary Arterial Smooth Muscle Cells via Modulation of CHOP

Ribas Andrade Manuella, Yun Xin, Shimoda Larissa

You have to be authorized to contact abstract author. Please, Login
Not Available